Article
Gene therapy for sickle cell disease and thalassemia
27 Feb 2025
Abstract excerpt
PURPOSE OF REVIEW: Thalassemia and sickle cell disease are among the most frequent monogenic hereditary diseases. Access to transfusions, iron chelation therapies and drugs such as hydroxyurea have improved life expectancy and quality of life. However, these diseases still cause significant disability. The first available curative therapy, bone marrow transplantation, is unfortunately not feasible for all...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
